Gas and the microbiome topical collection on neuromuscular disorders of the gastrointestinal tract

Current Gastroenterology Reports

Volumn 15, Issue 12, 2013, Pages

  Pimentel, Mark ^a   Mathur, Ruchi ^a   Chang, Christopher ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Intestinal gas; Microbiome

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CARBON DIOXIDE; CARBON MONOXIDE; HYDROGEN; HYDROGEN SULFIDE; LACTULOSE; METHANE; METRONIDAZOLE; NEOMYCIN; NITRIC OXIDE; RIFAXIMIN; VITAMIN;

ARCHAEON; ARTICLE; BACTERIAL OVERGROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTEROIDES THETAIOTAOMICRON; BIOSYNTHESIS; BLOATING; BODY MASS; BREATH ANALYSIS; CONSTIPATION; DEGRADATION; DISEASES; ENERGY YIELD; FERMENTATION; FUNGUS; GENETIC ASSOCIATION; GRAM NEGATIVE ANAEROBIC BACTERIA; HEALTH; HUMAN; IMMUNOMODULATION; INTESTINE; INTESTINE FLORA; IRRITABLE COLON; MEDIATOR; METHANOBACTERIALES; METHANOBREVIBACTER SMITHII; MICROBIAL COLONIZATION; MICROBIOME; NONHUMAN; NUTRIENT SUPPLY; PHENOTYPE; PNEUMATOSIS INTESTINALIS; GAS; METABOLISM; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY; REVIEW;

FERMENTATION; GASES; HUMANS; HYDROGEN; HYDROGEN SULFIDE; INTESTINES; METHANE; MICROBIOTA;

EID: 84890313696     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-013-0356-y     Document Type: Article

References (77)

1. The Gut Microbiota. Science (special issue). 2012;336.
2. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207-14.
3. A framework for human microbiome research. Nature. 2012;486:215-21.
4. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-80.
5. Sahakian AB, Jee SR, Pimentel M. Methane and the gastrointestinal tract. Dig Dis Sci. 2010;55:2135-43.
6. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31:107-33.
7. Conly JM, Stein K, Worobetz L, Rutledge-Harding S. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. Am J Gastroenterol. 1994;89:915-23.
8. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science N Y. 2006;312:1355-9. (Pubitemid 43839542)
9. Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr. 2002;22:283-307. (Pubitemid 35221463)
10. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101:15718-23. (Pubitemid 39473554)
11. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47:241-59. (Pubitemid 43276911)
12. Littman DR, Pamer EG. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe. 2011;10:311-23.
13. Salzman NH. Microbiota-immune system interaction: an uneasy alliance. Curr Opin Microbiol. 2011;14:99-105.
14. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc. 2008;83:460-9. (Pubitemid 351536471)
15. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104:979-84. (Pubitemid 46154722)
16. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027-31. (Pubitemid 46018515)
17. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-72. (Pubitemid 47025442)
18. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470-81.
19. Sanz Y, Santacruz A, Gauffin P. Gut microbiota in obesity and metabolic disorders. Proc Nutr Soc. 2010;69:434-41.
20. Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med. 2011;62:361-80.
21. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacol Ther. 2011;130:202-12.
22. Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol. 2009;15:2887-92.
23. Kerckhoffs AP, Visser MR, Samsom M, et al. Critical evaluation of diagnosing bacterial overgrowth in the proximal small intestine. J Clin Gastroenterol. 2008;42:1095-102.
24. Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EM. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam. 2012;2012:151085.
25. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:691-701.
26. Gibson GR, Cummings JH, Macfarlane GT. Competition for hydrogen between sulphate-reducing bacteria and methanogenic bacteria from the human large intestine. J Appl Bacteriol. 1988;65:241-7.
27. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53:1443-54.
28. Basseri RJ, Weitsman S, Barlow GM, Pimentel M. Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol. 2011;7:455-93.
29. Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55:2441-9.
30. King CE, Toskes PP. Small intestine bacterial overgrowth. Gastroenterology. 1979;76:1035-55. (Pubitemid 9250747)
31. Kaye SA, Lim SG, Taylor M, Patel S, Gillespie S, Black CM. Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br J Rheumatol. 1995;34:265-9.
32. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325:1461-7.
33. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107:28-35. quiz 6.
34. Weaver GA, Krause JA, Miller TL, Wolin MJ. Incidence of methanogenic bacteria in a sigmoidoscopy population: an association of methanogenic bacteria and diverticulosis. Gut. 1986;27:698-704. (Pubitemid 16085557)
35. Pochart P, Lemann F, Flourie B, Pellier P, Goderel I, Rambaud JC. Pyxigraphic sampling to enumerate methanogens and anaerobes in the right colon of healthy humans. Gastroenterology. 1993;105:1281-5. (Pubitemid 23315299)
36. Miller TL, Wolin MJ. Enumeration of Methanobrevibacter smithii in human feces. Arch Microbiol. 1982;131:14-8. (Pubitemid 12153065)
37. Bauchop T, Mountfort DO. Cellulose fermentation by a rumen anaerobic fungus in both the absence and the presence of rumen methanogens. Appl Environ Microbiol. 1981;42:1103-10. (Pubitemid 12164621)
38. McKay LF, Holbrook WP, Eastwood MA. Methane and hydrogen production by human intestinal anaerobic bacteria. Acta Pathol Microbiol Immunol Scand B. 1982;90:257-60. (Pubitemid 12074528)
39. Gibson GR, Cummings JH, Macfarlane GT, et al. Alternative pathways for hydrogen disposal during fermentation in the human colon. Gut. 1990;31:679-83. (Pubitemid 20209040)
40. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature. 2011;474:327-36.
41. Jones WJ, Nagle Jr DP, Whitman WB. Methanogens and the diversity of archaebacteria. Microbiol Rev. 1987;51:135-77. (Pubitemid 17037067)
42. Pimentel M, Mayer AG, Park S, Chow EJ, Hasan A, Kong Y. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci. 2003;48:86-92. (Pubitemid 36232767)
43. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412-9. (Pubitemid 36232393)
44. Kim G, Deepinder F, Morales W, et al. Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig Dis Sci. 2012.
45. • Mathur R, Kim G, Morales W, et al. Intestinal Methanobrevibacter smithii but Not Total Bacteria Is Related to Diet-Induced Weight Gain in Rats. Obesity (Silver Spring). 2012;21:748-54. This study demonstrated that methane is linked to a higher BMI.
46. Chatterjee S, Park S, Low K, Kong Y, Pimentel M. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol. 2007;102:837-41. (Pubitemid 46496615)
47. Kunkel D, Basseri RJ, Makhani MD, Chong K, Chang C, Pimentel M. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci. 2011;56:1612-8.
48. Attaluri A, Jackson M, Valestin J, Rao SS. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol. 2010;105:1407-11.
49. • Pimentel M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol. 2006;290:G1089-95. This study showed that methane itself slows gut transit. (Pubitemid 43788289)
50. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51:1297-301. (Pubitemid 44315794)
51. Pimentel M, Kong Y, Park S. IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. Dig Dis Sci. 2004;49:84-7. (Pubitemid 38183750)
52. Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009;106:2365-70.
53. Samuel BS, Gordon JI. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc Natl Acad Sci U S A. 2006;103:10011-6. (Pubitemid 43993614)
54. Samuel BS, Hansen EE, Manchester JK, et al. Genomic and metabolic adaptations of Methanobrevibacter smithii to the human gut. Proc Natl Acad Sci U S A. 2007;104:10643-8. (Pubitemid 47185718)
55. Schink B. Energetics of syntrophic cooperation in methanogenic degradation. Microbiol Mol Biol Rev. 1997;61:262-80. (Pubitemid 27283803)
56. McNeil NI. The contribution of the large intestine to energy supplies in man. Am J Clin Nutr. 1984;39:338-42. (Pubitemid 14186434)
57. Basseri RJ, Basseri B, Pimentel M, et al. Intestinal methane production in obese individuals is associated with a higher body mass index. Gastroenterol Hepatol. 2012;8:22-8.
58. Mathur R, Amichai M, Chua KS, Mirocha J, Barlow GM, Pimentel M. Methane and hydrogen positivity on breath test is associated with greater body mass index and body fat. J Clin Endocrinol Metab. 2013;98:E698-702.
59. Cesario V, Di Rienzo TA, Pitocco D, et al. Diabetes and gastrointestinal disorders: the effect of intestinal methane production on glycemic control gastroenterology. 2013;144:S-564.
60. Kim G, Giamarellos-Bourboulis EJ, Chang C, Pyleris E, Pistiki K, Pimentel M. Quantitation of bacteria in duodenal aspirates by qPCR appears to identify viable organisms in IBS gastroenterology. 2013;144:S-908.
61. Armougom F, Henry M, Vialettes B, Raccah D, Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PloS one. 2009;4:e7125.
62. Million M, Maraninchi M, Henry M, et al. Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. Int J Obes. 2012;36:817-25.
63. Million M, Angelakis E, Maraninchi M, et al. Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli. Int J Obes (2005) 2013.
64. Liou AP, Paziuk M, Luevano Jr JM, Machineni S, Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013;5:178ra41.
65. Patil DP, Dhotre DP, Chavan SG, et al. Molecular analysis of gut microbiota in obesity among Indian individuals. J Biosci. 2012;37:647-57.
66. Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44:547-50.
67. Dridi B, Fardeau ML, Ollivier B, Raoult D, Drancourt M. The antimicrobial resistance pattern of cultured human methanogens reflects the unique phylogenetic position of archaea. J Antimicrob Chemother. 2011;66:2038-44.
68. Marvin-Sikkema FD, Rees E, Kraak MN, Gottschal JC, Prins RA. Influence of metronidazole, CO, CO(2), and methanogens on the fermentative metabolism of the Anaerobic Fungus Neocallimastix sp. Strain L2. Appl Environ Microbiol. 1993;59:2678-83. (Pubitemid 23223014)
69. Medani M, Collins D, Docherty NG, Baird AW, O'Connell PR, Winter DC. Emerging role of hydrogen sulfide in colonic physiology and pathophysiology. Inflamm Bowel Dis. 2011;17:1620-5.
70. Schemann M, Grundy D. Role of hydrogen sulfide in visceral nociception. Gut. 2009;58:744-7.
71. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev. 2012;92:791-896.
72. Rey FE, Gonzalez MD, Cheng J, Wu M, Ahern PP, Gordon JI. Metabolic niche of a prominent sulfate-reducing human gut bacterium. Proc Natl Acad Sci U S A. 2013;110:13582-7.
73. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev. 2007;6:917-35. (Pubitemid 350042399)
74. Yang G, Wu L, Jiang B, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science. 2008;322:587-90.
75. Schicho R, Krueger D, Zeller F, et al. Hydrogen sulfide is a novel prosecretory neuromodulator in the Guinea-pig and human colon. Gastroenterology. 2006;131:1542-52. (Pubitemid 44708939)
76. Gallego D, Clave P, Donovan J, et al. The gaseous mediator, hydrogen sulphide, inhibits in vitro motor patterns in the human, rat and mouse colon and jejunum. Neurogastroenterol Motil. 2008;20:1306-16.
77. Picton R, Eggo MC, Langman MJ, Singh S. Impaired detoxication of hydrogen sulfide in ulcerative colitis? Dig Dis Sci. 2007;52:373-8. (Pubitemid 46202808)